| No antibody | Erbitux ® (anti-ErB1) | Herceptin ® (anti-ErB2) |
---|
U87Ctrl
|
130.1±4.4
|
98.3±8.6(*)
|
125.6±7.9 (ns)
|
U87dn
|
144.3±3.3
|
104.3±3.9(*)
|
131.6±8.8 (ns)
|
- Cells were plated at 7,500 cells/cm2 in 96-well culture dishes and were grown in the presence of 1% FCS in the presence or absence of EREG (30 ng/ml), Erbitux® (200 μg/ml; cetuximab) and Herceptin® (830 μg/ml; trastuzumab). Cells were counted in triplicate after four days of culture. EREG-induced cell proliferation was presented as mean percentage ± SD of the total cell number measured in the absence of EREG (100% reference value). Mann–Whitney was performed for significance: Erbitux® vs. no antibody (*; p ≤ 0.05); Herceptin® vs. no antibody (ns, not significant; p > 0.05).